MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Levodopa-induced orthostatic hypotension in a large cohort of patients with Parkinson’s disease undergoing an acute levodopa challenge test

    X. Wang, S. Mei, C. Han, P. Chan (Beijing, China)

    Objective: We aimed to investigate the frequency and associated risk factors for Levodopa-induced orthostatic hypotension (OH) in a large cohort of PD patients underwent acute…
  • 2023 International Congress

    Rasagiline in Chinese patients with early-stage parkinson’s disease: a randomized, double-blind, placebo-controlled, delayed-start trial

    W. Su, HJ. Liu, LJ. Wang, QY. Ye, L. Cao, HY. Zhou, XG. Luo, ZT. Ding, T. Wang, Q. Wang, HZ. Ma, EH. Xu, HB. Chen (Beijing, China)

    Objective: Objective: This randomized, double-blind, placebo-controlled, delayed-start trial aimed to investigate the efficacy in symptom improvement and disease-modifying effect of rasagiline for Chinese patients with…
  • 2023 International Congress

    Diplopia (Double vision) in Parkinson’s disease patients: prevalence and nonmotor effect

    EL. Ungureanu, KR. Chaudhuri, ș. Diaconu, L. Irincu, R. Filip, B. Ciopleiaș, C. Falup-Pecurariu (Brasov, Romania)

    Objective: To assess the prevalence of diplopia in Parkinson’s disease (PD) patients and the correlation of diplopia with visual hallucinations, cognitive dysfunction and motor performance.…
  • 2023 International Congress

    Fluorescence-lifetime ophthalmoscopy findings in Parkinson’s disease patients with visual disturbances

    K. Shivok, E. Affel, M. Alizadeh, T-W. Liang, D. Kremens, R. Sergott (Philadelphia, USA)

    Objective: We identified fluorescence-lifetime ophthalmoscopy changes in Parkinson’s disease (PD) patients experiencing visual disturbances. Background: Fluorescence-lifetime ophthalmoscopy (FLIO), a novel in vivo imaging method generating…
  • 2023 International Congress

    Targeting autophagy to identify novel modulators of Parkinson’s disease using midbrain organoids

    J. Jarazo, I. Rosety, C. Serra-Almeida, R. Marques, C. Saraiva, R. Davis, J. Schwamborn (Esch-sur-Alzette, Luxembourg)

    Objective: Natural compound libraries are a great source of new chemical molecules that could restore the altered phenotypes in patient derived cells. The objective of…
  • 2023 International Congress

    Gray matter volume changes in occipital and temporal visual brain region are associated with freezing of gait in Parkinson’s

    YX. Li, ZL. Luo, XL. Yang (Kunming, China)

    Objective: This study aimed to investigate the association of changed gray matter volume(GMV)with Freezing of gait(FOG) in Parkinson’s disease(PD). Background: FOG is a characteristic gait…
  • 2023 International Congress

    Epigenome-wide meta-analysis of sex-differential DNA methylation in Parkinson’s disease

    T. Yang, C. Li, Q. Wei, R. Ou, Y. Cheng, K. Liu, J. Lin, Y. Xiao, H. Shang (Chengdu, China)

    Objective: To comprehensively characterize the blood-based DNA methylation alterations related to sex in patients with Parkinson's disease (PD), shedding light on the underlying genes and…
  • 2023 International Congress

    Connectomic DBS informed multifocal transcranial direct current stimulation (tDCS) in Parkinson’s Disease: a crossover double blinded study

    L L. Goede, S. Oxenford, D. Kroneberg, G M. Meyer, N. Rajamani, C. Neudorfer, P. Krause, R. Lofredi, M D. Fox, A A. Kühn, A. Horn (Berlin, Germany)

    Objective: To determine if non-invasive neuromodulation of a network previously identified through invasive neuromodulation could improve motor symptoms in Parkinson's disease (PD). Background: A recent…
  • 2023 International Congress

    Motor complications in Parkinson’s disease

    S. Gandhi, T. Zerenner, A. Nodehi, M. Lawton, K. Grosset, V. Marshall, F. Al-Hajraf, Y. Ben-Shlomo, M. Hu, D. Grosset (Glasgow, United Kingdom)

    Objective: To determine the presence, severity, functional impact and predisposing factors of motor complications. Background: Motor complications are well recognized in Parkinson’s disease (PD), but…
  • 2023 International Congress

    Design of a Phase 2 Study of Suvecaltamide in Moderate to Severe Parkinson’s Disease Tremor

    R. Hauser, C. Adler, G. Deuschl, M. Baladi, P. Chandler, T. Skarpass, K. Xu, P. Lewitt (Tampa, USA)

    Objective: Describe the design of a phase 2 study (NCT05642442) of a once-daily, extended-release formulation of suvecaltamide to treat moderate to severe Parkinson’s disease tremor…
  • « Previous Page
  • 1
  • …
  • 249
  • 250
  • 251
  • 252
  • 253
  • …
  • 436
  • Next Page »
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley